AHAustin Hamp

Austin Hamp

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Austin Hamp has a total of 41 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Analysis of Dermatology Content by Top Influencers on Twitter and Their Academic Impact: Cross-Sectional Study

    by Mindy D Szeto, Andrina V Mamo, Kevin Kamel, Jadesola T Olayinka, Payal M Patel, Austin Hamp, Jarett Anderson, Lori S Kim, Madeleine G Yemc, Torunn E Sivesind, et al.

    Journal of Medical Internet Research - International Scientific Journal for Medical Research, Information and Communication on the Internet #Preprint #PeerReviewMe: Warning: This is a unreviewed preprint. Readers are warned that the document has not been peer-reviewed by expert/patient reviewers or an academic editor, may contain misleading claims, and is likely to undergo changes before final publication, if accepted, or may have been rejected/withdrawn. Readers with interest and expertise are encouraged to sign up as peer-reviewer, if the paper is within an open peer-review period. Please cite this preprint only for review purposes or for grant applications and CVs (if you are the author). -


  • Dupilumab-associated mycosis fungoides: a cross-sectional study

    by Austin Hamp, Jamie Hanson, Robert A. Schwartz, W. Clark Lambert, Albert Alhatem

    Treating atopic dermatitis (AD) with dupilumab, a monoclonal antibody that inhibits interleukin-4 (IL-4) and interleukin-13 (IL-13), may be associated with the progression of mycosis fungoides (MF). This study aims to examine the associations between the length of dupilumab treatment, age and sex, and the onset of MF. An institutional data registry and literature search were used for a retrospective cross-sectional study. Only patients with a diagnosis of MF on dupilumab for the treatment of AD and eczematous dermatitis were included. The primary outcome was the length of dupilumab exposure, age, sex, and the onset of MF. Linear correlations (Pearson) and Cox regression analysis were used to assess the correlation and the risk. A total of 25 patients were included in this study. Five eligible patients were identified at our institution. In addition, a PubMed review identified an additional 20 patients. At the time of MF diagnosis, the median age was 58, with 42% female. Disease history was significant for adult-onset AD in most patients (n = 17, 65.4%) or recent flare of AD previously in remission (n = 3, 11.5%). All patients were diagnosed with MF, and one patient progressed to Sézary syndrome while on dupilumab, with an average duration of 13.5 months of therapy prior to diagnosis. Tumor stage at diagnosis of MF was described in 19 of the cases and ranged from an early-stage disease (IA) to advanced disease (IV). Treatment strategies included narrow-band UVB therapy, topical corticosteroids, brentuximab, pralatrexate, and acitretin. Male gender, advanced-stage disease, and older age correlated significantly with the hazard of MF onset and a shorter time to onset during dupilumab treatment. Our results suggest a correlation between the duration of dupilumab treatment and the diagnosis of MF, the higher MF stage at diagnosis, and the shorter the duration of using dupilumab to MF onset. Furthermore, elderly male patients appeared to be more at risk as both male gender and older age correlated with a hazard of MF diagnosis. The results raise the question as to whether the patients had MF misdiagnosed as AD that was unmasked by dupilumab or if MF truly is an adverse effect of treatment with dupilumab. Close monitoring of these patients and further investigation of the relationship between dupilumab and MF can shed more light on this question .


  • Open Access

    Gua‐sha, Jade Roller, and Facial Massage: Are there benefits within dermatology?

    by Austin Hamp, Jarett Anderson, Melissa R. Laughter, Jaclyn B. Anderson, Colby L. Presley, Chandler W. Rundle, Robert P. Dellavalle


  • Open Access

    Dupilumab-Associated Mycosis Fungoides; A Cross-Sectional Study

    by Austin Hamp, Jamie Hanson, Robert A Schwartz, W. Clark Lambert, Albert Alhatem

    Importance: Treating AD with dupilumab, a monoclonal antibody that inhibits interleukin-4 (IL-4) and interleukin-13 (IL-13), may be associated with progression of MF. Objective: To examine the associations between length of dupilumab treatment, age and sex, and onset of MF. Design, Setting, and Participants: An institutional data registry and literature search were used for a retrospective cross-sectional study. Only patients with a diagnosis of MF on dupilumab for the treatment of AD and eczematous dermatitis were included. Exposure: AD patients treated with dupilumab. Main Outcomes and Measures: The primary outcome was the length of dupilmab exposure, age and sex, and MF onset. Linear correlations (Pearson) and Cox regression analysis were used to assess the correlation and the risk. Results: Five eligible patients were identified at our institution. In addition, the PubMed review identified an additional 20 patients. The median age was 58 years, with 42% female. Disease history was significant for adult-onset AD in most patients (n=17, 65.4%) or recent flare of AD previously in remission (n=3, 11.5%). All patients were diagnosed with MF, and one patient progressed to Sezary syndrome while on dupilumab, with an average duration of 13.5 months of therapy prior to diagnosis. Tumor stage was described in 19 of the cases and ranged from an early-stage disease (IA) to advanced disease (IV). Treatment strategies included narrow-band UVB therapy, topical corticosteroids, brentuximab, praladextrate, and acitretin. Male gender, advanced-stage disease, and older age correlated significantly with the hazard of MF onset and a shorter time to onset during dupilumab treatment. Conclusion and Relevance: Our results suggest a correlation between the duration of dupilumab treatment and the diagnosis of MF, the higher MF stage at diagnosis the shorter the duration of using dupilumab to MF onset. Furthermore, elderly male patients appeared to be more at risk as both male gender and older age correlated with hazard of MF diagnosis. The results raise the question as to whether the patients had MF misdiagnosed as AD that was unmasked by dupilumab or if MF truly is an adverse effect of treatment with dupilumab. Close Monitoring of these patients and further investigation of the relationship between dupilumab and MF can shed more light into this question.

  • Open Access

    Emojis and Emoticons in Health Care and Dermatology Communication: Narrative Review

    by Mindy D Szeto, Cara Barber, Varun K Ranpariya, Jarett Anderson, Jonny Hatch, Jordan Ward, Megan N Aguilera, Shahzeb Hassan, Austin Hamp, Tyler Coolman, et al.

    Background: Emoticons and emojis have become staple additions to modern-day communication. These graphical icons are now embedded in daily society through the various forms of popular social media and through users’ personal electronic conversations. With ever-increasing use and inclusivity, exploration of the possible health care and dermatology applications of these tools is imperative. Objective: The goal of this narrative review was to provide and evaluate an up-to-date literature survey examining the utility of emoticons and emojis in medicine. Special attention was paid to their existing and potential uses in the field of dermatology, especially during the COVID-19 pandemic. Methods: A PubMed search of peer-reviewed publications was performed in mid-2021 to collect articles with emoticon or emoji keywords in combination with other health care–relevant or dermatology-relevant keywords. Screening of publications and described studies was performed by the authors with education and research experience in health care, dermatology, social media, and electronic communication trends. Selected articles were grouped based on common subjects for qualitative analysis and presentation for in-depth discussion. Results: From this extensive search, researchers were able to identify a wide variety of publications detailing the use of emoticons and emojis in general health care, pediatric health care, public health, and dermatology. Key subject areas that emerged from the investigation included the ability of emoticons and emojis to improve communication within pediatric health care, enhance mood and psychological assessment or mental health screening in adults, develop interventions to improve patient medication adherence, complement novel means of public health and COVID-19 surveillance, and bolster dermatology-specific applications. Conclusions: This review illuminated the repurposing of emojis and emoticons for a myriad of advantageous functions in health care and public health, with applications studied in many populations and situations. Dermatology-specific uses were relatively sparse in the literature, highlighting potential opportunities for growth in future studies and practices. The importance of diversity and inclusivity has extended to emojis, with the recent introduction of skin color customization and new emojis better representing the comprehensive spectrum of users’ experiences. A continuously evolving and technology-driven population creates a unique niche for emoticons and emojis to ease worldwide communication and understanding, transcending the barriers of age, language, and background. We encourage future studies and innovations to better understand and expand their utility.


  • Open Access

    Analysis of Dermatology Content by Top Influencers on Twitter and Their Academic Impact: Cross-Sectional Study (Preprint)

    by Mindy D Szeto, Andrina V Mamo, Kevin Kamel, Jadesola T Olayinka, Payal M Patel, Austin Hamp, Jarett Anderson, Lori S Kim, Madeleine G Yemc, Torunn E Sivesind, et al.

    Journal of Medical Internet Research - International Scientific Journal for Medical Research, Information and Communication on the Internet #Preprint #PeerReviewMe: Warning: This is a unreviewed preprint. Readers are warned that the document has not been peer-reviewed by expert/patient reviewers or an academic editor, may contain misleading claims, and is likely to undergo changes before final publication, if accepted, or may have been rejected/withdrawn. Readers with interest and expertise are encouraged to sign up as peer-reviewer, if the paper is within an open peer-review period. Please cite this preprint only for review purposes or for grant applications and CVs (if you are the author). -

  • Open Access

    From the Cochrane Library: Topical Tacrolimus for Atopic Dermatitis

    by Austin Hamp, Jarett D Anderson, Torunn E Sivesind, Mindy D Szeto, Jade Cury-Martins


  • Open Access

    Emojis and Emoticons in Healthcare and Dermatology Communication: A Narrative Review (Preprint)

    by Mindy D Szeto, Cara Barber, Varun K Ranpariya, Jarett Anderson, Jonny Hatch, Jordan Ward, Megan N Aguilera, Shahzeb Hassan, Austin Hamp, Tyler Coolman, et al.

    BACKGROUND Emoticons and emojis have become staple additions to modern day communication. These graphical icons are now imbedded into daily society through the various forms of popular social media and through users’ personal electronic conversations. With ever increasing use and inclusivity, exploration of the possible healthcare and dermatology applications of these tools is imperative. OBJECTIVE The goal of this narrative review is to provide and evaluate an up-to-date literature survey examining the utility of emoticons and emojis in medicine. Special attention will be drawn to existing and potential usage in the field of dermatology, especially during the COVID-19 pandemic. METHODS A PubMed search of peer-reviewed publications was performed in mid-2021 to collect articles with emoticon or emoji keywords in combination with other healthcare or dermatology-relevant keywords. Screening of publications and described studies was performed by authors with education and research experience in healthcare, dermatology, social media, and electronic communication trends. Selected articles were grouped by common subjects to be qualitatively analyzed and presented for in-depth discussion. RESULTS From this extensive search, researchers were able to identify a wide variety of publications detailing the use of emoticons and emojis within general healthcare, pediatric healthcare, public health, and dermatology. Key subject areas that emerged from the investigation included the ability of emoticons or emojis to improve communication within pediatric healthcare, enhance mood and psychological assessment or mental health screening in adults, develop interventions to improve patient medication adherence, complement novel means of public health and COVID-19 surveillance, and bolster dermatology-specific applications. CONCLUSIONS This review illuminated the repurposing of emojis or emoticons for a myriad of advantageous functions in the healthcare and public health, with applications studied in many populations and situations. Dermatology-specific uses were relatively sparse in the literature, which highlights a potential opportunity for growth in future studies and practices. The importance of diversity and inclusivity has extended to emojis, with the recent introduction of Skin of Color customization and new emojis better representing the comprehensive spectrum of users’ experiences. A continuously evolving and technology-driven population creates a unique niche for emoticons and emojis to ease worldwide communication and understanding, transcending barriers of age, language, and background. We encourage future studies and innovation to further understand and expand their utility.

  • Open Access

    From the Cochrane Library: Systemic Treatments for Metastatic Cutaneous Melanoma

    by Austin Hamp, Jarett Anderson, Torunn E Sivesind, Mindy D Szeto, Andreas Hadjinicolaou


  • Open Access

    A Scoping Review of Social Media Sites as a Tool for Clinical Trial Recruitment and Retention (Preprint)

    by Jarett Anderson, Austin Hamp, Michelle Militello, Ryan Geist, Jaclyn Anderson, Melissa R Laughter, Colby L. Presley, Chandler Rundle

    BACKGROUND Clinical trials are an essential process in discovering new biomedical or behavioral outcomes in disease processes. There are several steps involved in creating a clinical trial. One step, patient recruitment, is often touted as the largest contributor to trial delays, which has financial, scientific, and ethical ramifications. Approximately 1.2 billion dollars in the United States is spent each year on this process and as many as 86% of clinical trials do not meet recruitment targets within their perspective timeframes, and 19% of trials had to be terminated early due to insufficient recruitment and/or patient retention1. Social media is a viable, inexpensive tool that can be utilized to improve both recruitment and retention rates2. To date, platforms such as Facebook, Twitter and others have been widely utilized in recruitment for clinical trials, communication among stakeholders, and educational tools. Social media also has the advantage of reaching populations that otherwise would be more difficult to reach3. A list of these platforms and each of their distinct advantages for clinical trial recruitment can be found in Table 1. This review aims to highlight the unique characteristics of several social media platforms and their advantageous properties in increasing recruitment and retention during clinical trials. OBJECTIVE This narrative review analyzes the current use of several social media sites in clinical trial recruitment and retention. It also offers insight concerning potential uses of these sites that are not currently utilized. METHODS A literature search was performed using PubMed, Google Scholar, and ResearchGate to access and review relevant articles published in peer-reviewed journals concerning social media and its use in clinical trials. Two independent researchers with education and experience in dermatology screened publications to select studies featuring quantitative results concerning social media and clinical trial recruitment. RESULTS 13 social media applications were studied and reviewed. 7 of these social media sites or applications have currently been studied, and their use in complementing traditional recruiting methods such as advertisements in newspapers, health fairs, and direct mailing, has been analyzed and reported. 6 additional social media applications have further been studied, and their potential use within clinical trial research has been additionally analyzed. CONCLUSIONS A large number and variety of social media platforms exist to aid in the recruitment and retention process for clinical trials, many of which can utilize niche features and reach a targeted demographic. Although recruitment remains a barrier for researchers involved in clinical trials, the potential to recruit through social media may be underutilized. Many avenues that exist to improve recruitment have not been leveraged. For example, partnering to create collaborative videos with social media influencers on platforms such as Instagram and Youtube may help to broaden the audience and increase clinical trial enrollments. Creating biomedical educational profiles or channels that discuss details of clinical trials with descriptions of these trials could also be employed to increase the scope of the audience. Reddit, Smart Patients, and Patients Like Me can target difficult-to-reach patient populations due to their use of subgroups, allowing researchers to reach their target audience. Additionally, many of these platforms provide user engagement features that allow users to respond directly to videos or posts and could be used to encourage enrollment by allowing users to react directly to clinical trial advertisements.